PURPOSE: The aim of this study was to evaluate long-term clinical treatment with OROS methylphenidate (MPH) (Concerta) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH. METHODS: Subjects aged 6-16 years (n=105) who were stable on IR MPH (10-60 mg/day) were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators. RESULTS: Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10-16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS MPH was well tolerated. CONCLUSIONS: Children and adolescents can effectively and safely be switched from IR MPH to OROS MPH with improved symptom control and compliance.
PURPOSE: The aim of this study was to evaluate long-term clinical treatment with OROS methylphenidate (MPH) (Concerta) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH. METHODS: Subjects aged 6-16 years (n=105) who were stable on IR MPH (10-60 mg/day) were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators. RESULTS: Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10-16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS MPH was well tolerated. CONCLUSIONS:Children and adolescents can effectively and safely be switched from IR MPH to OROS MPH with improved symptom control and compliance.
Authors: Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-02 Impact factor: 8.829
Authors: Timothy E Wilens; Keith McBurnett; Oscar Bukstein; James McGough; Laurence Greenhill; Marc Lerner; Mark A Stein; C Keith Conners; John Duby; Jeffrey Newcorn; Charles E Bailey; Christopher J Kratochvil; Daniel Coury; Charles Casat; Mary Joan C Denisco; Patricia Halstead; Leslie Bloom; Brenda A Zimmerman; Joan Gu; Kimberly M Cooper; Joseph M Lynch Journal: Arch Pediatr Adolesc Med Date: 2006-01
Authors: W E Pelham; E M Gnagy; L Burrows-Maclean; A Williams; G A Fabiano; S M Morrisey; A M Chronis; G L Forehand; C A Nguyen; M T Hoffman; T M Lock; K Fielbelkorn; E K Coles; C J Panahon; R L Steiner; D L Meichenbaum; A N Onyango; G D Morse Journal: Pediatrics Date: 2001-06 Impact factor: 7.124
Authors: H Remschmidt; P Hoare; C Ettrich; A Rothenberger; P Santosh; M Schmidt; Q Spender; R Tamhne; M Thompson; C Tinline; G E Trott; R Medori Journal: Eur Child Adolesc Psychiatry Date: 2005-09 Impact factor: 4.785
Authors: Timothy Wilens; William Pelham; Mark Stein; C Keith Conners; Howard Abikoff; Marc Atkins; Gerald August; Laurence Greenhill; Keith McBurnett; Donna Palumbo; James Swanson; Mark Wolraich Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-04 Impact factor: 8.829
Authors: Stan Kutcher; Michael Aman; Sarah J Brooks; Jan Buitelaar; Emma van Daalen; Jörg Fegert; Robert L Findling; Sandra Fisman; Laurence L Greenhill; Michael Huss; Vivek Kusumakar; Daniel Pine; Eric Taylor; Sam Tyano Journal: Eur Neuropsychopharmacol Date: 2004-01 Impact factor: 4.600
Authors: J R Valdizán-Usón; A Cánovas-Martínez; M T De Lucas-Taracena; F Díaz-Atienza; L S Eddy-Ives; A Fernández-Jaén; M Fernández-Pérez; M García-Giral; P García-Magán; M Garraus-Oneca; M A Idiazábal-Alecha; M López-Benito; G Lorenzo-Sanz; J Martínez-Antón; M A Martínez-Granero; F Montañés-Rada; F Mulas-Delgado; G Ochando-Perales; E Ortega-García; A Pelaz-Antolín; J A Ramos-Quiroga; F C Ruiz-Sanz; J Vaquerizo-Madrid; A Yusta-Izquierdo Journal: Neuropsychiatr Dis Treat Date: 2013-02-08 Impact factor: 2.570